Back to Single Peptide Protocols
Single PeptideImmune & Inflammation5 mg vialTwice weeklySubcutaneousImmunomodulatory
Thymosin Alpha-1 (5 mg Vial) Dosage Protocol
Thymosin Alpha-1 dosage protocol for the 5 mg vial. Immunomodulatory peptide with clinical evidence for immune enhancement and antiviral activity.
Vial Size
5 mg
Route
Subcutaneous
Frequency
Twice weekly
Dose Range
1.6–3.2 mg twice weekly
Dosage Schedule
| Period | Dose |
|---|---|
| Standard protocol | 1.6 mg |
| High-dose protocol | 3.2 mg |
Route: Subcutaneous · Frequency: Twice weekly · Cycle: 6–12 weeks
How It Works
Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide derived from prothymosin alpha that modulates T-cell maturation, NK cell activity, and cytokine production. It is approved in 35+ countries as Zadaxin for hepatitis B/C and immunodeficiency.
Potential Benefits
- •Approved in 35+ countries (Zadaxin) for hepatitis B/C and immunodeficiency.
- •Enhances T-cell and NK cell function.
- •Antiviral and anti-tumor properties in clinical trials.
- •Studied for COVID-19 immune support.
Side Effects & Risks
- •Mild injection-site reactions.
- •Generally very well-tolerated in clinical studies.
Important Notes
- Approved as Zadaxin in 35+ countries.
- Research-use only in the US.
- Studied extensively for viral hepatitis and cancer immunotherapy.
Storage Instructions
- Lyophilized: −20 °C (−4 °F).
- Once mixed: 2–8 °C; use within 7 days.
References
- [1]Goldstein AL et al. Thymosin alpha1: clinical applications and mechanisms of action. Ann N Y Acad Sci 2007.View Source
Research & Educational Use Only: This protocol is for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making any decisions related to peptides or any other compounds.